Aura Biosciences Inc.

Aura Biosciences Inc. specializes in the development and commercialization of targeted therapies for the treatment of various forms of cancer. The company's primary focus is on creating therapies that utilize its proprietary Virus-Like Drug Conjugate (VDC) technology platform, which has the potential to selectively target and destroy cancer cells while sparing healthy tissue. This innovative approach aims to provide effective treatment options with fewer side effects compared to traditional chemotherapy or radiation treatments. Aura Biosciences primarily impacts the biotechnology and pharmaceutical sectors, contributing to advancements in oncology therapeutics. As a player in the biotech market, Aura attracts attention with its ongoing research and development efforts aimed at addressing unmet medical needs in oncology, particularly in understudied and challenging cancer types.